BeiGene to Present at the Bernstein 36th Annual Strategic Decisions Conference

Rhea-AI Summary

BeiGene, a biotechnology firm, will present at the Bernstein 36th Annual Strategic Decisions Conference on May 27, 2020, at 8:00 a.m. ET. The event will be accessible via a live webcast on BeiGene's investor website, with an archived replay available for 90 days. Founded with the aim of improving cancer treatment outcomes, BeiGene offers innovative drugs including the BTK inhibitor BRUKINSA and anti-PD-1 antibody tislelizumab. With over 3,800 employees across several regions, BeiGene remains committed to advancing cancer therapeutics.

News Market Reaction – BGNE

-1.79%

1 alert

-1.79% News Effect

On the day this news was published, BGNE declined 1.79%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

CAMBRIDGE, Mass. and BEIJING, China, May 20, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the Company will present at the Bernstein 36^th Annual Strategic Decisions Conference on Wednesday, May 27, 2020 at 8:00 a.m. ET.

A live webcast can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com or http://hkexir.beigene.com. An archived replay will be available following the event for 90 days.

About BeiGene

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 3,800+ employees in China, the United States, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer. We currently market two internally-discovered oncology products: BTK inhibitor BRUKINSA™ (zanubrutinib) in the United States, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.

Investor Contact
Craig West
+1 857-302-5189
ir@beigene.com

Media Contact
Liza Heapes or Vivian Ni
+1 857-302-5663 or +1 857-302-7596
media@beigene.com

FAQ

When will BeiGene present at the 36th Annual Strategic Decisions Conference?

BeiGene will present on May 27, 2020, at 8:00 a.m. ET.

How can I access the BeiGene conference presentation?

The presentation can be accessed via a live webcast on BeiGene's investor website.

What is BeiGene's focus as a biotechnology company?

BeiGene focuses on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for cancer treatment.

What products does BeiGene currently market?

BeiGene markets BTK inhibitor BRUKINSA and anti-PD-1 antibody tislelizumab, among others.

How long will the archived replay of BeiGene's presentation be available?

The archived replay will be available for 90 days after the event.